Most upper tract urothelial carcinomas (UTUC) are muscle invasive at the time of diagnosis. Current standard methods for the diagnosis of UTUC are invasive. Urine cytology is the only non-invasive test for detecting UTUC, but its sensitivity is low. A novel non-invasive assay for UTUC detection would improve patient outcome. This study aimed to investigate the mutation of cell-free DNA (cfDNA) in urine supernatant to develop a reliable diagnostic biomarker for UTUC patients. We studied urinary cfDNA from 153 individuals, including 56 patients with localized UTUC, and carried out droplet digital PCR assay for TERT promoter and FGFR3 hotspot mutations. We could detect mutations of TERT C228T in 22/56 (39.3%), TERT C250T in 4/56 (7.1%), and FGFR3 S249C in 9/56 (16.1%) patients. FGFR3 mutation was detected only in ≤pT1 tumors (positive predictive value: 100.0%). In combination with cytology results, the sensitivity was 78.6%, and the specificity was 96.0%. Although these data need to be validated in a larger-scale cohort, mutation analysis of TERT promoter and FGFR3 in urinary cfDNA has the potential to be a non-invasive diagnostic marker and reliable factor for tumor staging.
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| INTRODUC TI ON
Upper tract urothelial carcinoma arising from the renal pelvis or ureter is a relatively uncommon malignancy, accounting for 5% of UC.
1 Fifty-five to fifty-nine percent of UTUC are muscle invasive at the time of diagnosis. 2, 3 Patients suspected of having UTUC need to receive invasive procedures such as computed tomography (CT) urography, retrograde pyelography, or ureteroscopy for a definitive diagnosis. Many researchers have tried to develop useful urinary markers to detect UTUC, 4, 5 but urine cytology still remains the only non-invasive diagnostic marker recommended by many guidelines 6, 7 although its sensitivity for detection of UTUC is as low as 40%.
8
Cell-free DNA in bodily fluids has huge potential in disease diagnosis. [9] [10] [11] Cell-free tumor DNA is shed into the urine or circulation along with DNA from normal cells. Even though ctDNA constitutes a small fraction of the total DNA, ctDNA is thought to be a promising diagnostic biomarker. Christensen et al 12 reported the prognostic utility of urinary and plasma ctDNA extracted from patients with UBC.
Next-generation sequencing has shown genomic alterations and transcriptional subtypes in UTUC and UBC tissue. [13] [14] [15] [16] Hotspot mutations of TERT promoter and FGFR3 (S249C) are fre- 
| MATERIAL S AND ME THODS

| Urine samples
We investigated voided urine samples from four cohorts of patients: those with localized UTUC (UTUC cohort); those with microscopic or macroscopic hematuria without UC (hematuria cohort); those who were treated with TURBT or RNU and had no evidence of disease recurrence for at least 1 year (UC surveillance cohort); and a healthy control cohort (HC cohort) that included kidney transplantation donors, healthy volunteers, benign disease patients (ie, benign prostate hyperplasia or acute cystitis), and patients with urological carcinoma other than UC. All patients were treated at Osaka University Hospital, Osaka General
Medical Center, or Osaka Police Hospital from 2013 to 2019. All patients provided written informed consent, and the study was approved by the appropriate ethics committee. All patients in the UTUC cohort were histologically diagnosed as having UC, and urine samples were collected from patients within 4 days before RNU or transurethral biopsy. We excluded UTUC patients with concurrent bladder cancer. In 12 of the patients in the UTUC cohort, post-treatment urine samples were also collected approximately 1 week after RNU.
| Pathological diagnosis
Histological diagnosis was determined by experienced pathologists.
Tumor stage and grade were determined according to the 8th edition of the AJCC stage classification, 23 and tumors were graded according to the World Health Organization 2016 criteria. 24 Urine cytology was also evaluated by specialists according to our institutional criteria, in which negative urine cytology is defined to be no more than class III and positive urine cytology to be class IV and class V.
We used the highest urine cytology class for data analysis if patients received several cytology tests before treatment.
| Urinary cfDNA purification
After collection from the patients, urine was centrifuged at 2000 g for 30 minutes, and urine supernatants were stored at −80°C. Urine was thawed in a water bath at 27°C, and 4-32 mL (median: 12 mL) supernatants was used for cfDNA purification after centrifugation at 16 000 g for 10 minutes. 
| Droplet digital PCR assay
For mutation detection, we used the ddPCR platform QX100 Droplet Digital PCR System (Bio-Rad Laboratories, Hercules, CA, USA), including primers and probes (FAM, mutant type; HEX, wild type), and ddPCR Supermix for Probes (No dUTP) according to the manufacturer's protocol. For every experiment, we used a positive control corresponding to each mutation. Primers and probes for ddPCR were TERT promoters C228T/C250T, FGFR3 S249C, and PIK3CA E545K (Table S1 ). Droplets were generated using a droplet generator (BioRad Laboratories). The PCR cycle for FGFR3 included a 10-minute incubation at 95°C followed by 40 cycles at 94°C for 30 seconds and at 55°C for 1 minute, one cycle at 98°C for 10 minutes, and a 12°C hold; and that for the TERT promoter included a 10-minute incubation at 95°C followed by 50 cycles at 94°C for 30 seconds and at 55°C for 1 minute, one cycle at 98°C for 10 minutes, and a 12°C hold. We used 5.7 ng (range: 1.5-30.7 ng) of urinary cfDNA for each ddPCR analysis. Droplet fluorescence was assessed in a droplet reader. Analysis of ddPCR data for allele calling and calculation of absolute copy numbers were done using QuantaSoft software version 1.7.4 (Bio-Rad Laboratories). The samples were considered positive for targeted mutations when they met two criteria: (i) they contained at least three droplets in the positive area of the FAM signal; and (ii) the MAF was >0.1%. MAF was defined as the proportion of copies of the mutant type relative to the sum of copies of the mutant and wild type obtained by the ddPCR platform.
| Statistical analysis
Statistical analysis was carried out using JMP Pro 14.0.0 (SAS Institute Inc., Cary, NC, USA). Patient characteristics were compared using the Mann-Whitney U test. Multiple regression analyses were done to assess the relative contributions of factors (age, gender and urine cytology) and the mutations in cfDNA. Differences were considered statistically significant when P < 0.05. at the time of RNU, and three (5.4%) patients died from UTUC during follow up. Hotspot mutation analysis of cfDNA in urine supernatant extracted from all of these patients was carried out (Figure 1 ).
| RE SULTS
The amount of cfDNA extracted from the UC surveillance cohort and HC cohort was significantly lower than that from the UTUC patients ( Figure S1A TA B L E 1 Summary of patient cohort and mutational status F I G U R E 1 Schematic view of the present study. cfDNA, cell-free DNA grade and low grade ( Figure S1B,C) . There was no association between mutant copy number and pathological grade or stage ( Figure   S1D ,E Figure 2 ). Because the detection rate of mutant PIK3CA was very low and overlapped with other mutations, hereafter, we focus on the analysis of FGFR3 and TERT promoters (C228T and C250T). There was no association between the rate of mutation detection and smoking history, but more mutations were detected in older patients (75%, 21/28) than in younger ones (35.7%, 10/28; P = 0.031; Figure 2 (Table 3) .
A TERT promoter mutation was detected in two of the 21 pa- After excluding two patients who, respectively, received BCG therapy or platinum-based chemotherapy without RNU, we analyzed 54 UTUC patients for survival. However, no significant difference was observed in prognosis (bladder recurrence-free survival or overall survival) between TERT promoter mutation and wild type ( Figure 4A,B) . UTUC patients with high MAF of the TERT C228T mutation in urinary cfDNA had shorter overall survival than those with low MAF (P = 0.040) ( Figure S2A ). In contrast, MAF of TERT C228T mutation was not associated with bladder recurrence-free survival among patients with TERT C228T mutation (P = 0.110) ( Figure S2B ).
There was no association between overall survival and tumor copies in urine in the overall cohort (P = 0.899) ( Figure S2C ).
Of the 12 patients in whom both pre-and post-surgery urinary cfDNA could be analyzed, clearance of ctDNA after RNU was confirmed in seven (58.3%) patients, but in two patients (16.7%), ctDNA persisted even after RNU ( Figure 4C ). The patients in whom ctDNA TA B L E 3 Sensitivity, specificity, PPV, and NPV of each parameter F I G U R E 4 Association between cell-free tumor DNA (ctDNA) and outcome. A, Bladder recurrence-free survival stratified by TERT promoter mutation. B, Overall survival of patients stratified by TERT promoter mutation. C, Change of ctDNA level before and after radical nephroureterectomy (RNU). D, Bladder recurrence-free survival stratified by TERT promoter mutation in post-RNU urine persisted tended to have a worse prognosis for recurrence of nonmuscle-invasive urothelial bladder carcinoma compared with those who experienced clearance of ctDNA (P = 0.081) ( Figure 4D ). In six samples, we also investigated DNA of matched samples from FFPE specimens by ddPCR. We were able to confirm the same genetic status in the urinary cfDNA, which was consistent with the DNA from the FFPE specimens.
| D ISCUSS I ON
In this proof-of-concept study, we showed the diagnostic potential of the TERT promoter and FGFR3 mutations detected by ddPCR of cfDNA extracted from urine supernatant of patients with localized UTUC.
There have been several studies on urinary pellet DNA and urine supernatant cfDNA from UBC patients. Various mutations could be detected in urinary pellet DNA, [25] [26] [27] and in urinary cfDNA (PIK3CA E545K). In the current study, we could detect mutations at rates of 39.3% (TERT C228T), 7.1% (TERT C250T), 16.1% (FGFR3 S249C), and 8.9% (PIK3CA E545K) in urinary cfDNA in Japanese patients. The difference in detection rates may be due to differences of the cohorts investigated because as Springer et al reported, the Taiwanese cohort was highly exposed to aristolochic acid, a known carcinogenic and nephrotoxic agent in Aristolochia herbs, whereas our Japanese cohorts were not.
Because hematuria has high sensitivity for detecting urothelial carcinoma, it is useful for mass screening. However, as a result of the low specificity of hematuria, an additional specific test is necessary to make a definitive diagnosis of UTUC. Urine cytology is a non-invasive test and is often chosen because of its high specificity as a primary approach by the physician to differentiate urological malignancies from benign diseases such as hematuria or dysuria.
However, its sensitivity for diagnosis is relatively low, 16%-84% in UBC 29 and 40% in UTUC. 8 In the present study, we could detect the three targeted gene mutations (TERT C228T, TERT C250T, and FGFR3 S249C) in 55.4% of urine samples from UTUC patients. In combination with urine cytology, our non-invasive method could have high sensitivity (78.6%) for the detection of UTUC and be useful in making a definitive diagnosis. To some extent, UTUC shares the same gene alterations as UBC, so this method might also be a useful tool for detecting UBC for bladder surveillance after RNU.
In bladder tumors, the TERT promoter mutation occurs frequently in precancerous lesions and in low-grade UBC, high-grade UBC, squamous cell carcinoma of the urinary bladder, adenocarcinoma of the urinary bladder, micropapillary urothelial carcinoma and plasmacytoid urothelial carcinoma. 18, [30] [31] [32] [33] [34] [35] Thus, the TERT promoter mutation has been established as a common genetic alteration in UC.
We could detect TERT promoter mutation at any stage of UTUC, and this finding also supports the fact that TERT promoter mutation occurs as an early genetic event in carcinogenesis. Moreover, several researchers reported that TERT promoter mutation is associated with bladder recurrence and survival in UBC. 36 38 Christensen et al 12 showed a significant association between ctDNA level and tumor grade and also that the amount of ctDNA from patients whose DNA extracted from bladder tumor tissue was mutation positive was significantly associated with progression-free survival or recurrence-free survival. However, in the present study, we could not find a significant association between ctDNA level and prognosis. This may be a result of the small sample cohort and short observation period. In this study, a post-RNU TERT promoter mutation tended to be associated with worse prognosis for bladder recurrence in UTUC. Larger-scale studies are necessary to confirm these findings in UTUC.
Besides TERT promoter mutation, we selected FGFR3 mutation as an additional biomarker candidate. Sfakianos to offer ureteroscopic nephron-sparing surgery for patients with low-risk UTUC. In this study, the sensitivity and PPV for detecting ≤T1 tumor by FGFR3 S249C were 32.1% and 100.0%, respectively.
Although the sensitivity is relatively low, a positive result of an FGFR3 mutation in urinary cfDNA could help to predict a low-stage tumor as a liquid biopsy not requiring tissue examination. This assay for FGFR3 mutation may have the potential to become an alternative for ureteroscopy and a reliable factor for deciding whether to carry out ureteroscopic nephron-sparing surgery.
This study has several limitations because of its small population size and short follow-up period. The median age of the hematuria cohort is significantly younger than that of the UTUC cohort. Because there was an association between age and the prevalence of mutation in the UTUC cohort, the difference in age between the UTUC and hematuria cohorts could have influenced the positive rate of detecting mutant cfDNA. However, there are no reports of an increased rate of TERT promoter mutation in healthy elderly compared with healthy young persons. Further prospective large-scale studies and a longer follow-up period are warranted to confirm our findings. TP53 is well known as one of the key players in carcinogenesis and is frequently mutated in UC. Although our urinary cfDNA ddPCR assay targeting three hotspot mutations has low sensitivity for detecting UTUC, massive parallel sequencing of multiple genes could be applicable to the analysis of urinary cfDNA and might increase sensitivity, thus providing more benefit to patients. 16 In combination with the results of cytology, our assay for urinary cfDNA may lead to an earlier diagnosis of UTUC and optimized follow-up strategy and may help the physician avoid an invasive procedure to determine a definitive diagnosis. In conclusion, we could detect TERT promoter and FGFR3 hotspot mutations in urinary cfDNA from UTUC patients. In combination with cytology results, the sensitivity of our non-invasive urinary test was high enough to apply this assay to the clinical setting. Liquid biopsy analysis of TERT promoter and FGFR3 mutations in urinary cfDNA could be a novel diagnostic biomarker and a reliable factor for staging UTUC.
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